ncRNA-Mediated High Expression of LPCAT1 Correlates with Poor Prognosis and Tumor Immune Infiltration of Liver Hepatocellular Carcinoma

J Immunol Res. 2022 May 16:2022:1584397. doi: 10.1155/2022/1584397. eCollection 2022.

Abstract

Purpose: To investigate the expression of LPCAT1 in liver hepatocellular carcinoma (LIHC) and its relationship with prognosis and immune infiltration and predict its upstream nonencoding RNAs (ncRNAs).

Method: In this study, expression analysis and survival analysis for LPCAT1 in pan cancers were first performed by using The Cancer Genome Atlas (TCGA) data, which suggested that LPCAT1 might be a potential LIHC oncogene. Then, ncRNAs contributing to the overexpression of LPCAT1 were explored in starBase by a combination of expression analysis, correlation analysis, and survival analysis. Immune cell infiltration of LPCAT1 in LIHC was finally investigated via Tumor Immune Estimation Resource (TIMER).

Result: SNHG3 was observed to be the most promising upstream lncRNA for the hsa-miR-139-5p/LPCAT1 axis in LIHC. In addition, the LPCAT1 level was significantly positively associated with tumor immune cell infiltration, biomarkers of immune cells, and immune checkpoint expression in LIHC.

Conclusion: To summarize, the upregulation of LPCAT1 mediated by ncRNAs is associated with poor prognosis, immune infiltration, and immune checkpoint expression in LIHC.

MeSH terms

  • 1-Acylglycerophosphocholine O-Acyltransferase* / genetics
  • Biomarkers, Tumor / genetics
  • Carcinoma, Hepatocellular* / diagnosis
  • Carcinoma, Hepatocellular* / genetics
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Liver Neoplasms* / immunology
  • Liver Neoplasms* / pathology
  • MicroRNAs* / genetics
  • Prognosis
  • RNA, Untranslated* / genetics

Substances

  • Biomarkers, Tumor
  • MIRN139 microRNA, human
  • MicroRNAs
  • RNA, Untranslated
  • 1-Acylglycerophosphocholine O-Acyltransferase
  • Lpcat1 protein, human